Johnson & Johnson stock gains as guidance points to 2026 revenue above USD 100 billion

Published on 09/15/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock trades near its 52-week high as of September 15, 2026, supported by management’s forecast for 2026 operational sales growth of 6.5% and EPS growth of 7.3%. The company also beat expectations in its latest quarter with USD 25.31 billion in revenue and adjusted EPS of USD 2.90.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) is trading close to its 52-week high as of September 15, 2026, while management is guiding for adjusted operational sales growth of 6.5% and adjusted EPS growth of 7.3% for 2026, with annual revenue expected to exceed USD 100 billion for the first time.Investing.com reports that this long-range growth case was outlined at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.

Conference guidance underpins growth story

According to Investing.com on September 14, 2026, Johnson & Johnson used the Morgan Stanley 24th Annual Global Healthcare Conference to outline guidance for 2026 adjusted operational sales growth of 6.5% and adjusted EPS growth of 7.3%, signaling mid-single-digit to high-single-digit expansion in its core metrics.

In the same conference appearance, executives indicated that total revenue in 2026 is projected to surpass USD 100 billion for the first time in the company’s history, framing 2027 as even stronger than 2026 and targeting double-digit growth by the end of the decade.Investing.com notes that this path relies on new drug launches and a focused portfolio rather than major mergers and acquisitions.

Recent quarterly results beat expectations

Johnson & Johnson’s latest reported quarter also supports the optimism embedded in its guidance. As MarketBeat highlights on September 15, 2026, the company delivered adjusted EPS of USD 2.90 and revenue of USD 25.31 billion in its most recent quarter, topping consensus estimates of USD 2.84 per share and USD 25.06 billion in revenue.

That quarterly revenue of USD 25.31 billion was up 6.6% year over year compared with the USD 2.77 EPS reported in the same period a year earlier, illustrating how earnings per share increased by roughly USD 0.13 while sales grew mid-single digits on an annual basis.MarketBeat reports that the quarter produced a net margin of 21.48% and a return on equity of 32.42%, underscoring robust profitability and capital efficiency.

Analyst views and price targets remain supportive

On the analyst side, sentiment toward Johnson & Johnson stock remains broadly positive. According to MarketBeat on September 15, 2026, one research analyst currently rates the stock Strong Buy, eighteen assign a Buy rating and six suggest Hold, resulting in a consensus rating of Moderate Buy with an average price target of USD 274.13.

In addition, Futunn reports on September 15, 2026, that TD Cowen initiated coverage of Johnson & Johnson with a Buy rating and a target price of USD 300, positioning the stock roughly USD 33 above the MarketBeat consensus target and indicating additional upside potential in that specific research view.

Pipeline developments and valuation considerations

Beyond headline financials, Johnson & Johnson’s pipeline and product performance are key to sustaining its growth ambitions. As Investing.com notes, immunology drug TREMFYA posted 74% growth in the second quarter, and management indicated that it leads in initiation shares in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, thereby providing a concrete growth engine within the portfolio.

At the same time, valuation has become a point of discussion. According to GuruFocus on September 14, 2026, Johnson & Johnson shares trade around USD 266.32, which the outlet’s GF Value metric estimates to be 37.8% above an intrinsic value of USD 193.33, implying the stock is significantly overvalued on that proprietary model even as the company maintains a dividend yield near 1.95% with a moderate payout ratio and a three-year dividend growth rate of 4.9%.

Dividend profile and earnings guidance

The dividend remains an important pillar for many Johnson & Johnson shareholders. As MarketBeat reports, the company recently paid a quarterly dividend of USD 1.34 per share on September 8, 2026, to shareholders of record on August 25, 2026, corresponding to an annualized dividend of USD 5.36 and a dividend yield of about 2.0% at prevailing prices, with a dividend payout ratio of roughly 62.11%.

Looking ahead, Johnson & Johnson has set its full-year 2026 EPS guidance in a range of USD 11.60 to USD 11.75, and sell-side analysts on average project EPS of around USD 11.61 for the current fiscal year, aligning closely with management’s outlook.MarketBeat indicates that this guidance has been reaffirmed alongside the recent quarterly beat, reinforcing the narrative of steady mid-single-digit earnings growth.

Stock price near 52-week high

In the market, Johnson & Johnson stock is trading close to its recent highs. Per data for the New York Stock Exchange listing compiled by Robinhood, the shares changed hands at approximately USD 266.99 on September 15, 2026, after reaching an intraday high of USD 271.54 and a low of USD 266.22 during the same session, with trading volume of about 4,740,000 shares versus an average volume of 6,070,000 shares.Robinhood also reports a market capitalization of roughly USD 641.83 billion, highlighting the company’s status as a large-cap defensive name within healthcare.